NASDAQ$PTCT
PTC Therapeutics, Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
PTC Therapeutics reported strong revenue growth, expanded its product portfolio, and advanced its pipeline.
PTC Therapeutics reported a total revenue of $165.5 million for the second quarter of 2022, representing a 42% year-over-year growth. The company's Duchenne muscular dystrophy (DMD) franchise continued to show strong growth. Upstaza™ gene therapy was granted marketing authorization by the European Commission for the treatment of AADC deficiency.
- Total revenue reached $166 million, a 42% increase year-over-year.
- Duchenne muscular dystrophy (DMD) franchise revenue grew to $134 million, a 32% increase year-over-year.
- Translarna™ revenue increased 46% year-over-year to $77 million.
- Emflaza® revenue grew 16% year-over-year to $57 million.
Headline financials
Revenue & EPS history
PTC Therapeutics · Revenue · Quarterly
$166M
Revenue by segment
PTC Therapeutics · $134M total across 2 segments · Q2 2022
- Translarna$77M+46.4%57.5%
- Emflaza$56.8M+15.7%42.5%
Forward guidance
PTC anticipates total revenues for the full year 2022 to be between $700 and $750 million. PTC anticipates net product revenues for the DMD franchise for the full year 2022 to be between $475 and $495 million. PTC anticipates GAAP R&D and SG&A expense for the full year 2022 to be between $915 and $965 million. PTC anticipates Non-GAAP R&D and SG&A expense for the full year 2022 to be between $800 and $850 million, excluding estimated non-cash, stock-based compensation expense of $115 million.
Tailwinds
- Total revenues for the full year 2022 are expected to be between $700 and $750 million.
- Net product revenues for the DMD franchise for the full year 2022 are projected to be between $475 and $495 million.
- GAAP R&D and SG&A expense for the full year 2022 are anticipated to be between $915 and $965 million.
- Non-GAAP R&D and SG&A expense for the full year 2022 are projected to be between $800 and $850 million, excluding stock-based compensation expense.
- Continued investment in research programs and advancement of the clinical pipeline.
Headwinds
- Stock-based compensation expense is excluded from Non-GAAP R&D and SG&A expense.
- There are significant risks in the development, regulatory approval and commercialization of new products.
- The outcome of pricing, coverage and reimbursement negotiations with third-party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future.
- Dependence on Roche on Evrysdi sales.
- The company's strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-2.2%
Avg return
Earnings day
+1.2%
Avg return
5 days after
+5.8%
Avg return
30 days after
46%
26 / 57 earnings
Positive
+24.1%
Q2 2016
Best reaction
-34.0%
Q3 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | +14.0% | +10.1% | |
| Q4 2025 | +1.1% | -3.1% | -6.6% | |
| Q3 2025 | -1.1% | +3.3% | +6.4% | |
| Q1 2025 | +12.8% | +27.1% | +44.0% | |
| Q4 2024 | +9.3% | +2.7% | +7.3% | |
| Q3 2024 | +2.5% | +3.3% | +11.3% | |
| Q2 2024 | -1.8% | +0.1% | -1.0% | |
| Q1 2024 | +13.3% | +27.5% | +47.6% | |
| Q4 2023 | +13.3% | +11.0% | +3.2% | |
| Q3 2023 | -20.5% | -19.5% | -6.9% | |
| Q2 2023 | -3.7% | -2.9% | -0.3% | |
| Q1 2023 | +5.6% | +5.2% | -18.3% | |
| Q4 2022 | -5.2% | -7.4% | -0.0% | |
| Q3 2022 | -15.7% | -17.3% | -12.9% | |
| Q2 2022 | +11.9% | +8.2% | +8.5% | |
| Q1 2022 | +1.5% | -7.8% | -24.9% | |
| Q4 2021 | -8.8% | -8.7% | -4.1% | |
| Q3 2021 | +7.0% | +12.4% | +7.4% | |
| Q2 2021 | -2.9% | -2.3% | +7.3% | |
| Q1 2021 | +0.3% | -1.3% | -5.6% | |
| Q4 2020 | -0.9% | -0.5% | -14.6% | |
| Q3 2020 | -0.5% | +8.4% | +22.0% | |
| Q2 2020 | -3.0% | -0.9% | -1.0% | |
| Q1 2020 | -10.3% | -7.9% | -5.3% | |
| Q4 2019 | -5.4% | +0.4% | -18.7% | |
| Q3 2019 | +1.9% | +2.4% | +16.8% | |
| Q2 2019 | +8.6% | +10.4% | +1.5% | |
| Q1 2019 | +1.4% | -1.2% | +10.5% | |
| Q4 2018 | +0.9% | -0.7% | +6.8% | |
| Q3 2018 | -12.4% | -14.9% | -13.4% | |
| Q2 2018 | +7.2% | +14.9% | +15.4% | |
| Q1 2018 | -4.7% | -2.6% | +22.8% | |
| Q4 2017 | +10.0% | +8.0% | -2.4% | |
| Q3 2017 | -1.9% | -5.2% | -11.2% | |
| Q2 2017 | -2.1% | -4.7% | +4.3% | |
| Q1 2017 | -3.8% | +6.6% | +26.3% | |
| Q4 2016 | -16.9% | -23.2% | -4.8% | |
| Q3 2016 | -34.0% | -11.2% | +74.5% | |
| Q2 2016 | +24.1% | +24.6% | +26.4% | |
| Q1 2016 | +1.7% | — | — | |
| Q4 2015 | -30.5% | — | — | |
| Q3 2015 | +4.3% | — | — | |
| Q2 2015 | +0.4% | — | — | |
| Q1 2015 | -11.2% | — | — | |
| Q4 2014 | -4.3% | — | — | |
| Q3 2014 | +3.3% | — | — | |
| Q2 2014 | -12.5% | — | — | |
| Q1 2013 | -5.7% | — | — | |
| Q1 2014 | -5.7% | — | — | |
| Q4 2013 | -8.4% | — | — | |
| Q1 2012 | -8.4% | — | — | |
| Q4 2011 | -8.4% | — | — | |
| Q3 2012 | -10.7% | — | — | |
| Q3 2013 | -10.7% | — | — | |
| Q2 2013 | +1.2% | — | — | |
| Q2 2012 | +1.2% | — | — | |
| Q4 2012 | +1.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro